{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:59:20Z","timestamp":1785495560860,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Heidelberg der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pulmonary arterial hypertension (PAH) is characterized by right ventricular (RV) pressure overload, dilatation and dysfunction, which are key prognostic determinants. While riociguat improves exercise capacity and hemodynamics, prospective data on reverse remodeling remain limited. This prospective, phase IV study evaluated the effects of riociguat on right-heart size, function, hemodynamics, exercise capacity and safety in PAH patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Treatment-na\u00efve or pretreated PAH patients were enrolled. Patients receiving phosphodiesterase-5 inhibitors (PDE5i) could be switched to riociguat upon clinical indication. The primary endpoint was the change in right atrial (RA) and RV area at 24 weeks. Secondary endpoints included additional echocardiographic, clinical, exercise, hemodynamic and laboratory parameters, as well as quality-of-life (QoL) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty patients (61.2\u2009\u00b1\u200914.5 years; 76.7% male; 24 PDE5i-pretreated) were enrolled. Marked right-heart dilatation and impaired RV function were prominent at baseline. At week 24, riociguat significantly reduced RA (\u0394 -3.17\u2009\u00b1\u20095.91\u00a0cm\u00b2;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006) and RV area (\u0394 -6.00\u2009\u00b1\u20093.80\u00a0cm\u00b2;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Furthermore, RV-fractional area change, 6-minute walking distance and functional class improved significantly. In patients with invasive follow-up, cardiac index increased significantly, with favorable trends in further parameters. N-terminal pro-brain natriuretic peptide and QoL remained unchanged. The study terminated early following the decision by the supplier Merck\/MSD; the termination was not safety related. Riociguat was generally well tolerated with no new safety concerns.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Riociguat therapy resulted in a statistically significant improvement in right ventricular and atrial size and function with further improvements in exercise capacity and functional class. This prospective trial confirms the findings of previous retrospective studies and supports riociguat as an effective treatment option to improve RV geometry and performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This trial was registered on clinicaltrials.gov with the ClinicalTrials.gov ID NCT04954742.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-026-03843-8","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:24:29Z","timestamp":1785219869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of riociguat on right ventricular size and function in pulmonary arterial hypertension (RIVER II): a prospective, phase IV study"],"prefix":"10.1186","volume":"27","author":[{"given":"Satenik","family":"Harutyunova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faruk","family":"Sehic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Egenlauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cittadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Gr\u00fcnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7743-2472","authenticated-orcid":false,"given":"Panagiota","family":"Xanthouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"38","key":"3843_CR1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"issue":"4","key":"3843_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330\u201340.","journal-title":"N Engl J Med"},{"issue":"4","key":"3843_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"H-A Ghofrani","year":"2013","unstructured":"Ghofrani H-A, D\u2019Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med. 2013;369(4):319\u201329.","journal-title":"N Engl J Med"},{"issue":"25 Suppl","key":"3843_CR4","doi-asserted-by":"publisher","first-page":"D73","DOI":"10.1016\/j.jacc.2013.10.034","volume":"62","author":"VV McLaughlin","year":"2013","unstructured":"McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D73\u201381.","journal-title":"J Am Coll Cardiol"},{"key":"3843_CR5","doi-asserted-by":"crossref","unstructured":"Hemnes AR, Celermajer DS, D\u2019Alto M, Haddad F, Hassoun PM, Prins KW et al. Pathophysiology of the right ventricle and its pulmonary vascular interaction. Eur Respir J. 2024;64(4):2401321.","DOI":"10.1183\/13993003.01321-2024"},{"issue":"7","key":"3843_CR6","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0735-1097(02)01744-8","volume":"39","author":"RJ Raymond","year":"2002","unstructured":"Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002;39(7):1214\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3843_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2012.10.009","volume":"26","author":"E Bossone","year":"2013","unstructured":"Bossone E, D\u2019Andrea A, D\u2019Alto M, Citro R, Argiento P, Ferrara F, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr. 2013;26(1):1\u201314.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"3843_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12931-018-0913-x","volume":"19","author":"L Fischer","year":"2018","unstructured":"Fischer L, Benjamin N, Blank N, Egenlauf B, Fischer C, Harutyunova S, et al. Right heart size and function significantly correlate in patients with pulmonary arterial hypertension - a cross-sectional study. Respir Res. 2018;19(1):216.","journal-title":"Respir Res"},{"key":"3843_CR9","unstructured":"Badagliacca R, Poscia R, Pezzuto B, Papa S, Reali M, Pesce F et al. Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. J Heart Lung Transpl. 2017:S1053-2498(17)32041-7."},{"key":"3843_CR10","doi-asserted-by":"crossref","unstructured":"Amsallem M, Sweatt AJ, Aymami MC, Kuznetsova T, Selej M, Lu H et al. Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension: Comparison With Validated Models. Circ Cardiovasc Imaging. 2017;10(6):e005771.","DOI":"10.1161\/CIRCIMAGING.116.005771"},{"issue":"3","key":"3843_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.echo.2025.01.006","volume":"38","author":"M Mukherjee","year":"2025","unstructured":"Mukherjee M, Rudski LG, Addetia K, Afilalo J, D\u2019Alto M, Freed BH, et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2025;38(3):141\u201386.","journal-title":"J Am Soc Echocardiogr"},{"key":"3843_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijcard.2015.05.105","volume":"195","author":"AM Marra","year":"2015","unstructured":"Marra AM, Egenlauf B, Ehlken N, Fischer C, Eichstaedt C, Nagel C, et al. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2015;195:19\u201326.","journal-title":"Int J Cardiol"},{"issue":"1","key":"3843_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12931-018-0957-y","volume":"19","author":"AM Marra","year":"2018","unstructured":"Marra AM, Halank M, Benjamin N, Bossone E, Cittadini A, Eichstaedt CA, et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respir Res. 2018;19(1):258.","journal-title":"Respir Res"},{"issue":"6","key":"3843_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00408-018-0160-4","volume":"196","author":"IN Taran","year":"2018","unstructured":"Taran IN, Belevskaya AA, Saidova MA, Martynyuk TV, Chazova IE. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling. Lung. 2018;196(6):745\u201353.","journal-title":"Lung"},{"issue":"1","key":"3843_CR15","doi-asserted-by":"publisher","first-page":"e000667","DOI":"10.1136\/openhrt-2017-000667","volume":"5","author":"JZ Lee","year":"2018","unstructured":"Lee JZ, Low SW, Pasha AK, Howe CL, Lee KS, Suryanarayana PG. Comparison of tricuspid annular plane systolic excursion with fractional area change for the evaluation of right ventricular systolic function: a meta-analysis. Open Heart. 2018;5(1):e000667.","journal-title":"Open Heart"},{"issue":"9","key":"3843_CR16","doi-asserted-by":"publisher","first-page":"e009047","DOI":"10.1161\/CIRCIMAGING.119.009047","volume":"12","author":"K Tello","year":"2019","unstructured":"Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani HA, Naeije R, et al. Validation of the Tricuspid Annular Plane Systolic Excursion\/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. Circ Cardiovasc Imaging. 2019;12(9):e009047.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"3843_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.echo.2024.11.015","volume":"38","author":"N Benjamin","year":"2025","unstructured":"Benjamin N, Schiffer V, Resag C, Xanthouli P, Braun M, Harutyunova S, et al. Sex-Specific Differences in Echocardiographic Parameters of Risk Stratification in Pulmonary Arterial Hypertension. J Am Soc Echocardiogr. 2025;38(3):273\u201385.","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"3843_CR18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1183\/09031936.00090614","volume":"45","author":"LJ Rubin","year":"2015","unstructured":"Rubin LJ, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur Respir J. 2015;45(5):1303\u201313.","journal-title":"Eur Respir J"},{"issue":"10","key":"3843_CR19","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.healun.2021.06.020","volume":"40","author":"RL Benza","year":"2021","unstructured":"Benza RL, Ghofrani HA, Grunig E, Hoeper MM, Jansa P, Jing ZC, et al. Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. J Heart Lung Transpl. 2021;40(10):1172\u201380.","journal-title":"J Heart Lung Transpl"},{"issue":"8","key":"3843_CR20","doi-asserted-by":"publisher","first-page":"e43433","DOI":"10.1371\/journal.pone.0043433","volume":"7","author":"M Lang","year":"2012","unstructured":"Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS ONE. 2012;7(8):e43433.","journal-title":"PLoS ONE"},{"issue":"1","key":"3843_CR21","doi-asserted-by":"publisher","first-page":"204589321774611","DOI":"10.1177\/2045893217746111","volume":"8","author":"M Murata","year":"2018","unstructured":"Murata M, Kawakami T, Kataoka M, Kohno T, Itabashi Y, Fukuda K. Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension. Pulm Circ. 2018;8(1):2045893217746111.","journal-title":"Pulm Circ"},{"key":"3843_CR22","first-page":"3293584","volume":"2018","author":"N Rai","year":"2018","unstructured":"Rai N, Veeroju S, Schymura Y, Janssen W, Wietelmann A, Kojonazarov B, et al. Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. Biomed Res Int. 2018;2018:3293584.","journal-title":"Biomed Res Int"},{"key":"3843_CR23","doi-asserted-by":"crossref","unstructured":"Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D et al. RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. Eur Respir J. 2017;50(3):1602425.","DOI":"10.1183\/13993003.02425-2016"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03843-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:16:47Z","timestamp":1785493007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03843-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3843"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03843-8","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol and its amendments were approved by the local Ethics Committee of the Medical Faculty of Heidelberg University (Internal number AFmo-139\/2021) and the Federal Institute for Pharmaceuticals and Medical Products (BfArM) (EudraCT No. 2020-005462-34; EU CT No. 2023-509696-17-00), as well as registered at\n                      \n                      (NCT04954742) on 29 June 2021. The study was in line with the Declaration of Helsinki. Written informed consent was provided by all participants upfront participation in the trial.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data were anonymized, and no individual patient-identifiable information is included in this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SH: received travel fees, consulting fees, speaker fees, and\/or honoraria from Janssen, MSD, Bayer, AOP and OMT outside the submitted work. NB: speaker honoraria from University hospital Zurich, outside of this work. LB, JH, FS, AC: nothing to declare. BE: received travel fees, consulting fees, speaker fees, and\/or honoraria from AOP, Bayer, Boehringer, Johnson&Johnson, MSD and OMT outside the submitted work. AMM: receives research grants from the Italian Ministry of Healthcare and speaking fees foundation and grants, travel support and consultancy fees from MSD Italy, Boehringer-Ingelheim, Bayer, Astra-Zeneca, Bruno Farmaceutica, Laboratori Guidotti, all unrelated to the present work. EG: has received fees for lectures and\/or consultations from Bayer, MSD, Ferrer, AOP, Johnson Insmed and OMT. Research grants to his institution have been received from Acceleron, Bayer HealthCare, MSD, Johnson&Johnson, Novartis, OMT, Pfizer, Liquida, Insmed and United Therapeutics, outside the submitted work. PX: has received personal fees from Boehringer Ingelheim, Johnson&Johnson and MSD outside the submitted work.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"296"}}